ARA290
Investigational — Human trials in progressWhat it is
A short peptide (cibinetide) derived from erythropoietin, studied for neuropathic and inflammatory conditions in early human trials.
ARA-290 (cibinetide) is a short peptide derived from erythropoietin that does not raise red-cell counts, studied in early human trials for neuropathic and inflammatory conditions.
Research context
Studied in relation to:
- Neuropathy research
- Anti-inflammatory research
Points in its favour in the literature:
- Early human trial data exists
- Non-erythropoietic (doesn't raise red cells)
Caveats and unknowns:
- Investigational only
- Not approved
- Evidence still preliminary
Handling & reference data
Route in published researchSubcutaneous injection is the route most commonly described in the research literature.
Published clinical / research context (not instructions)Human trials used ~2–4 mg daily (investigational).
Storage (lyophilised)Lyophilised (freeze-dried) powder: refrigerate at 2–8 °C short-term, or freeze at −20 °C or below for long-term storage. Keep sealed and out of light.
Reconstituted solutionOnce reconstituted: keep refrigerated (2–8 °C), protect from light, do not freeze. With bacteriostatic water, commonly used within ~4 weeks; with plain sterile water, within ~24–48 h.
Worked reconstitution example (arithmetic only)e.g. 10 mg vial + 2 mL → 5 mg/mL.
Available research formats
| Strength | SKU |
|---|---|
| 10mg | RA10 |
Current pricing (THB with USD/GBP conversion) is shown live in the catalogue, which also has a transparent U-100 reconstitution calculator.